An interventional study of Ketogenic diet in Bipolar I Disorder, Schizoaffective Disorder and Psychosis, sponsored by Mclean Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Mclean Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Psychotic Disorders by Mclean Hospital — 6 open to participants now, 6 under way, none of them phase 3. Psychotic Disorders · Mclean Hospital.
Among the 18 studies in Psychotic Disorders by Mclean Hospital, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2024, is one of 11 with no phase, and was the 17th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →6 of the 18 studies in Psychotic Disorders by Mclean Hospital are open now, in 1 country. Recruiting first, the newest first:
Mclean Hospital · Sites in United States
Ages 18–55
Mclean Hospital · Sites in United States
Ages 18–45
Mclean Hospital · Sites in United States
Mclean Hospital · Sites in United States
Ages 18–55
Mclean Hospital · Sites in United States
Ages 18–50
By country, each count listing its studies:
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 50 across the 17 interventional studies, 187 across the 1 observational. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mclean Hospital is the lead sponsor of 185 studies on the registry; 31 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.
3 of the studies in Psychotic Disorders by Mclean Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07503093Mclean HospitalPilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis | 2027-05-01 |
| NCT06558201Mclean HospitalOpen Label Extension Study of NCT06221852 | 2027-09-30 |
| NCT06221852Mclean HospitalKetogenic and Nutritional Interventions for First Episode Bipolar Disorder | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Psychotic Disorders by Mclean Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 12-week open-label extension study for participants completing study NCT06221852.
In this 12-week single arm open label extension study of NCT06221852, the investigators aim to assess the longer term efficacy, safety and tolerability of the ketogenic diet in participants completing the randomized study phase of NCT06221852. Investigators will assess longer term effects on energy metabolism, insulin resistance and psychiatric symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-No longer meeting original entry criteria from the randomized 12-week study of NCT06221852.
Participants will be asked to follow the ketogenic diet (KD) for 12 weeks in addition to any ongoing medications (e.g., mood stabilizers and/or second-generation antipsychotics). Participants will receive diet counseling from a registered dietitian. Participants will be asked to monitor and report their blood ketone and glucose levels each day via a finger-prick device provided by the study team.
Other: Ketogenic diet
The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
Also known as: Keto diet
Change in brain redox nicotinamide adenine dinucleotide metabolites ratio (NAD+/NADH)
Change from baseline to week 24 in NAD+/NADH as measured by in vivo phosphorus magnetic resonance spectroscopy (31P-MRS).
Time frame: 24 weeks
Change in brain creatine kinase forward reaction rate (kf)
Change from baseline to week 24 in creatine kinase forward reaction rate (kf) as measured by 31P magnetization transfer (MT) MRS.
Time frame: 24 weeks
Change in insulin resistance
Change from baseline to week 24 of insulin resistance measured using the homeostatic model assessment of insulin resistance (HOMA-IR) using fasting blood glucose and insulin levels.
Time frame: 24 weeks
Change in psychotic symptoms
Change from baseline to week 24 in Positive and Negative Syndrome Scale (PANSS) total score. Scores range from 30-210; a higher score indicates a higher level of psychotic symptoms.
Time frame: 24 weeks
Change in depressive symptoms
Change from baseline to week 24 in Hamilton Rating Scale for Depression (HAM-D) total score. Scores range from 0-52; a higher score indicates a higher level of depression.
Time frame: 24 weeks
Change in mania symptoms
Change from baseline to week 24 in Young Mania Rating Scale (YMRS) total score. Scores range from 0-60. A higher score indicates a more severe illness.
Time frame: 24 weeks
Change in Clinical Global Impression (CGI) Scale
Change from baseline to week 24 in Clinical Global Impression (CGI) Scale. Scores range from 1-7; a higher score indicates higher severity of illness.
Time frame: 24 weeks
Change in body weight
Change from baseline to week 24 in participant body weight in kilograms, as measured using a standing scale.
Time frame: 24 weeks
Change in glycated hemoglobin (Hemoglobin A1c) level
Change from baseline to week 24 in fasting Hemoglobin A1c level.
Time frame: 24 weeks
Change in triglyceride levels
Change from baseline to week 24 in fasting triglyceride levels.
Time frame: 24 weeks
Change in low-density lipoprotein (LDL) levels
Change from baseline to week 24 in fasting LDL levels
Time frame: 24 weeks
Change in high-density lipoprotein (HDL) levels
Change from baseline to week 24 in fasting HDL levels
Time frame: 24 weeks
Change in high-sensitivity C-reactive protein (hs-CRP) levels
Change from baseline to week 24 in fasting hs-CRP levels.
Time frame: 24 weeks
Change in brain gamma-aminobutyric acid (GABA) concentration
Change from baseline to week 24 in GABA concentration measured by proton magnetic resonance spectroscopy.
Time frame: 24 weeks
Change in brain glutamate metabolite concentration
Change from baseline to week 24 in glutamate metabolite concentration measured by proton magnetic resonance spectroscopy.
Time frame: 24 weeks
Change in brain glutathione (GSH)
Change from baseline to week 24 in brain GSH measured by proton magnetic resonance spectroscopy.
Time frame: 24 weeks
Change in brain Phosphocreatine (PCr)
Changes from baseline to week 24 in PCr concentration as measured by in vivo 31P-MRS.
Time frame: 24 weeks
Change in brain pH
Change from baseline to week 24 in pH as measured by in vivo 31P MRS
Time frame: 24 weeks
Change in brain inorganic phosphate concentration
Change from baseline to week 24 in inorganic phosphate (Pi) concentration as measured by in vivo 31P MRS.
Time frame: 24 weeks
Change in adverse events
Change from baseline to week 24 in adverse events.
Time frame: 24 weeks
Change in anxiety symptoms
Change from baseline to week 24 from baseline to week 12 in Hamilton Anxiety Rating Scale (HAM-A) total score. Scores range from 0 - 56; a higher score indicates a higher level of anxiety.
Time frame: 24 weeks
Change in stress symptoms
Change from baseline to week 24 in Depression Anxiety Stress Scales (DASS-42) Stress Subscale score. Scores range from 0-42; a higher score indicates a higher level of stress.
Time frame: 24 weeks
Change in cognitive performance
Change from baseline to week 24 in Matrics Consensus Cognitive Battery (MCCB) Total Score. Scores range from 0.00% - 100.00%; a higher score indicates higher cognition.
Time frame: 24 weeks
Change in Global Functioning Scale (GFS) - Social and Role total score
Change from baseline to week 24 in Global Functioning Scale (GFS) - Social and Role total score. Scores range from 6-60; a lower score indicates worse social and role functioning.
Time frame: 24 weeks
Change in blood NAD/NADH+ ratio
Change from baseline to week 24 in blood NAD/NADH+ ratio.
Time frame: 24 weeks
Change in blood GSH/GSSH ratio
Change from baseline to week 24 in blood GSH/GSSH ratio.
Time frame: 24 weeks
Change in growth differentiation factor 15 (GDF15)
Change from baseline to week 24 in blood and saliva GDF15 levels.
Time frame: 24 weeks
Change in cell-free mitochondrial DNA (cf-mtDNA)
Change from baseline to week 24 in blood and saliva cf-mtDNA levels.
Time frame: 24 weeks
Change in World Health Organization Disability Assessment Schedule (WHODAS) score
Change from baseline to week 24 in World Health Organization Disability Assessment Schedule (WHODAS) scale. Scores range from 0-144. A higher score indicates greater dysfunction and disability in major life domains.
Time frame: 24 weeks
Change in World Health Organization Quality of Life (WHOQOL) score
Change from baseline to week 24 in World Health Organization Quality of Life (WHOQOL) scale. Scores range from 1-130. A lower score indicates lower perceived quality of life.
Time frame: 24 weeks
Change in Extrapyramidal Symptom Rating Scale (ESRS) total score
Change from baseline to week 24 in Extrapyramidal Symptom Rating Scale (ESRS) total score. Scores range from 0-102; a higher score indicates more severe symptoms.
Time frame: 24 weeks
Change in Pittsburgh Sleep Quality Index (PSQI) total score
Change from baseline to week 24 in Pittsburgh Sleep Quality Index (PSQI) total score. Scores range from 0-21; a higher score indicates worse sleep quality.
Time frame: 24 weeks
Change in resting-state fMRI
Change within network positive correlations and between network negative correlations from baseline to week 24.
Time frame: 24 weeks
Change in gray matter volume
Change in the gray matter volumes (cubic millimeters) of the frontal, parietal and temporal lobes as defined by Freesurfer's Desikan-Killiany Brain Atlas from baseline to week 24.
Time frame: 24 weeks
Change in cortical surface area
Change in the cortical surface area (millimeters squared) of the frontal, parietal and temporal lobes as defined by Freesurfer's Desikan-Killiany Brain Atlas from baseline to week 24.
Time frame: 24 weeks
Change in white matter fractional anisotropy (FA)
Change in fractional anisotropy (FA), a scalar measure of diffusivity, of water in the brain assessed by DTI at 3T from baseline to week 24. FA values range from 0 (isotropic, meaning diffusion is equally restricted in 3D space) to 1 (anisotrophic, meaning that diffusion is completely restricted to a single direction).
Time frame: 24 weeks
Started Aug 2024 (actual). Primary completion is estimated for Sep 2027, 37 months after the start.
Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 37 months is close to that.
Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.